← Back to Search

Sulfonylureas

Glyburide for Spinal Cord Injury (SCING Trial)

Phase 1
Recruiting
Research Sponsored by University of Kentucky
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No evidence of sepsis
Non-penetrating SCI at neurologic level from C2 to C8 or T1 to T12
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year post treatment
Awards & highlights

SCING Trial Summary

This trialtests if a diabetes drug can help protect spinal cord injury patients from further damage.

Who is the study for?
This trial is for adults with recent non-penetrating spinal cord injuries at certain levels, who are not in immediate life-threatening condition and can undergo neurological assessment within 8 hours. Excluded are those with severe heart issues, other major health problems like liver or kidney disease, low blood glucose levels, or a known allergy to sulfonylureas.Check my eligibility
What is being tested?
The study tests if Glyburide (Diabeta), an oral tablet commonly used for diabetes, can protect the nerves after acute traumatic injury to the cervical or thoracic spine. The goal is to see if it's safe and effective in improving outcomes for these patients.See study design
What are the potential side effects?
While specific side effects of Glyburide in this context aren't listed here, common ones include low blood sugar (hypoglycemia), nausea, headache, dizziness and potential allergic reactions. Side effects may vary based on individual patient conditions.

SCING Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I do not have sepsis.
Select...
My spinal cord injury is between my neck and mid-back without piercing the cord.
Select...
My spinal cord injury is severe but not complete, affecting my neck or upper back.
Select...
I have no life-threatening injuries from an accident.

SCING Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year post enrollment.
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year post enrollment. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of drug related adverse events.
Rate of recruitment of patients with tSCI within the specified time window.
Secondary outcome measures
Biomarker Analysis
Neurologic recovery following tSCI
Serum Pharmacokinetics to measure Glyburide concentrations.

SCING Trial Design

1Treatment groups
Experimental Treatment
Group I: Glyburide treatment armExperimental Treatment1 Intervention

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of KentuckyLead Sponsor
186 Previous Clinical Trials
226,672 Total Patients Enrolled

Media Library

Glyburide (Sulfonylureas) Clinical Trial Eligibility Overview. Trial Name: NCT05426681 — Phase 1
Spinal Cord Injury Research Study Groups: Glyburide treatment arm
Spinal Cord Injury Clinical Trial 2023: Glyburide Highlights & Side Effects. Trial Name: NCT05426681 — Phase 1
Glyburide (Sulfonylureas) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05426681 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the Glyburide treatment arm been authorized by the FDA?

"Since this is a Phase 1 trial, and the data on Glyburide's safety and efficacy are still quite limited, our team at Power has awarded it with a score of 1."

Answered by AI

Does this clinical trial accept participants younger than 25 years of age?

"As indicated by the inclusion criteria, only those aged 18 or older but not exceeding 80 years can partake in this medical trial."

Answered by AI

Does this clinical research accept participants at present?

"This medical study is currently recruiting participants, as indicated by the information found on clinicaltrials.gov. The trial was opened for recruitment on July 7th 2022 and has been revised most recently on October 20th 2022."

Answered by AI

How many participants are being tracked for this medical experiment?

"Affirmative. Records on clinicaltrials.gov demonstrate that this medical research, which was first published on July 7th 2022, is still recruiting volunteers. A total of 12 participants are needed at a single site."

Answered by AI

Who is eligible to participate in this experiment?

"Eligible participants to this clinical trial must possess a spinal cord and be between 18-80 years old. Around 12 applicants can join the study."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Spinal Cord Injury Neuroprotection With Glyburide
H. Francis Farhadi 2022. "Spinal Cord Injury Neuroprotection With Glyburide". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05426681.
~8 spots leftby May 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top